Aether Biomedical

Aether Biomedical

Produkcja sprzętu medycznego

Poznań, Wielkopolskie 6226 obserwujących

Making bionics accessible

Informacje

Aether Biomedical was founded on the premise of creating healthcare technology and robotics based on human-centered design. A culture focused on building the next generation of bionic devices, utilizing cutting-edge biosignal processing and software integration. After an expansion in Europe and Asia, we are now launching Zeus to the U.S market, with our U.S. headquarters in Chicago, IL. We have developed the Zeus hand, which is the strongest multi-articulating myoelectric hand in the world, providing 30-40% more grip force (152 Newtons) than existing market options! Apart from being the strongest hand, Zeus is highly robust as well. This is due to its patent-pending impact resistance mechanism which allows the fingers to flex when facing any impact, protecting them from breakage. Zeus is the first bionic hand that you can repair completely, within your workshop, in under 15 minutes. Incorporating 12 customizable grip patterns and a variety of control mechanisms. Zeus can be truly tailored to the patient’s usage profile. In conjunction with the Zeus hand, we are creating a digital ecosystem of mobile and software applications to improve the patient experience via technology and analytics. Zeus is supported by state-of-the-art web-based software that allows configuration of the hand via the web without the need to download applications to a computer. This web software allows you to track the history of the setting changes

Witryna
https://aetherbiomedical.com/
Branża
Produkcja sprzętu medycznego
Wielkość firmy
11–50 pracowników
Siedziba główna
Poznań, Wielkopolskie
Rodzaj
Spółka prywatna
Data założenia
2018
Specjalizacje
Medtech, Prosthetics, Rehabilitation, Innovation, Biotechnology, Robotics, Artificial intelligence i Electronics

Lokalizacje

Pracownicy Aether Biomedical

Aktualizacje

Podobne strony

Finansowanie

Aether Biomedical 9 suma pochyłych

Ostatnia runda

Seria A

5 800 000,00 USD

Zobacz więcej informacji na crunchbase